BeyondSpring (BYSI)
(Real Time Quote from BATS)
$1.94 USD
0.00 (0.00%)
Updated Aug 12, 2024 12:02 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BeyondSpring Inc. [BYSI]
Reports for Purchase
Showing records 41 - 60 ( 67 total )
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
2018 Results; This Year Is a Critical Year of Pivotal Data, Regulatory Filings and Addressing Cash Needs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
New Data Highlight Combo Regimen Plinabulin Plus Neulasta Could Improve CIN Therapy in Cancer Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Neutrophil Protection? Check. New Composition of Matter Protection? Check; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
What We Have Been Waiting for: Plinabulin Delivers on Phase 3 Interim; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Positive Data Continue to Accumulate Ahead of Anticipated China NDA Filing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
1Q18 Results; Phase 3 Data Coming and Pre-Commercialization Activities Underway
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
Prominent KOL Provides Feedback on Plinabulin Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
Company: BeyondSpring Inc.
Industry: Unclassified
Prospective and Randomized Differentiation of Plinabulin vs. Neulasta; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
2017 Results; Regulatory Filings in Sight; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
''105 Phase 3 Portion Hits the Ground Running; Possible NDA Filing With CFDA Within One Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
Fundamentals Continue to Improve; Management Change''s Impact on Shares Unwarranted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
Neutropenia Thought Leader Continues to Highlight Plinabulin Differentiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
Non-Inferiority Phase 2/3 Appears on Track for Success With Positive Phase 2 Portion
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
Plinabulin Validation Train Grows With New Data; KOL Gives Insight to Plinabulin Benefits
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
Plinabulin Hitting Major Designation Milestones in China
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
3Q17 Results; ASH Could Be Important Tipping Point; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
The China Thesis Takes an Important Leap Forward; Upping Price Target to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Unclassified
2Q17 Results; Reiterating Positive View Ahead of Phase 2 Interim Data This Year
Provider: H.C. Wainwright & Co., Inc.
Company: BeyondSpring Inc.
Industry: Unclassified
Important Looking Glass This Year Balanced With Potential Volatility; Increasing Price Target to $50
Provider: Rodman & Renshaw, Co.